Joseph T.
- Country
- Germany
- Department
- II. Medizinische Klinik und Poliklinik
Research Overview
- Phase 3 Randomized Double-Blind Study of INCA33890 Plus First-Line Chemotherapy and Bevacizumab in Metastatic Microsatellite Stable Colorectal Cancer
- Switch Maintenance with Paclitaxel, Ramucirumab and Tislelizumab vs Continued Chemotherapy plus Tislelizumab in HER2‑negative, PD‑L1‑positive Gastroesophageal Adenocarcinoma
- Phase 2 Open‑Label Study of BMS‑986504 Monotherapy and Combination Therapy in Advanced/Metastatic Solid Tumors with Homozygous MTAP Deletion
Data & Insights
Has run more than one trial at 76 of 263 partner sites.
Specializations
Hematologic malignancies
Joseph Tintelnot is involved in clinical research across a broad range of leukemia and lymphoma indications, including acute myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, diffuse large B-cell lymphoma, mantle cell lymphoma, and multiple myeloma. His research landscape also includes myelodysplastic syndrome, myelofibrosis, and central nervous system lymphoma.
- Acute myeloid leukemia
- Acute lymphoblastic leukemia
- Multiple myeloma
- Diffuse large B-cell lymphoma
His trial activity reflects a strong therapeutic focus on hematologic oncology, with interest in both newly diagnosed and relapsed or refractory disease settings.
Solid tumors and thoracic oncology
His clinical trial involvement spans multiple solid tumors, with particular attention to lung cancer, breast cancer, prostate cancer, ovarian cancer, pancreatic cancer, colorectal cancer, and head and neck squamous cell carcinoma. He is also engaged in studies of melanoma, renal cell carcinoma, urothelial carcinoma, and hepatocellular carcinoma.
- Non-small cell lung cancer
- Breast cancer
- Prostate cancer
- Ovarian cancer
This area of work highlights therapeutic interest in advanced and metastatic malignancies, including biomarker-defined tumor subsets.
Autoimmune, inflammatory, and dermatologic disease
Joseph Tintelnot participates in studies of hidradenitis suppurativa, atopic dermatitis, psoriasis, vitiligo, alopecia areata, rheumatoid arthritis, systemic lupus erythematosus, Sjögren’s syndrome, and systemic sclerosis. His research also extends to ulcerative colitis, celiac disease, and eosinophilic esophagitis.
- Hidradenitis suppurativa
- Psoriasis
- Atopic dermatitis
- Systemic autoimmune disease
His clinical interests include immune-mediated conditions requiring targeted anti-inflammatory and immunomodulatory treatment strategies.
Cardiovascular, renal, and transplant medicine
His trial portfolio includes atrial fibrillation, acute myocardial infarction, heart failure, atherosclerotic cardiovascular disease, stroke, and venous thromboembolism, alongside chronic kidney disease, glomerular disease, and kidney transplantation. He is also involved in research on antibody-mediated rejection, proteinuria, and renal allograft dysfunction.
- Atrial fibrillation
- Heart failure
- Chronic kidney disease
- Kidney transplantation
This work places emphasis on cardiovascular risk reduction, renal protection, and post-transplant care.
Neurology, rare disease, and infectious complications
Joseph Tintelnot’s research interests also include multiple sclerosis, dementia, glioblastoma, neuroblastoma, medulloblastoma, and spinal muscular atrophy. In parallel, he is involved in studies of amyloidosis, Fabry disease, mucopolysaccharidosis, and phenylketonuria, as well as cytomegalovirus infection, invasive fungal infection, and sepsis.
- Multiple sclerosis
- Rare genetic disease
- Neurologic malignancy
- Infectious disease
His clinical research landscape spans both chronic neurologic disorders and high-risk infectious complications in medically complex patients.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.